VivaChek Biotech

Executive Summary

VivaChek Biotech is a Chinese diagnostics company specializing in rapid point-of-care (POC) tests for infectious diseases, including HIV, hepatitis, and sexually transmitted infections. Founded in 2009 and based in Hangzhou, the company has developed a portfolio of lateral flow assays aimed at increasing testing accessibility in clinical and community settings. As a private, commercial-stage firm with 50–200 employees, VivaChek competes in the growing POC diagnostics market, which is driven by demand for decentralized testing and rapid results. The company's products are positioned to serve both domestic and international markets, with a focus on affordability and ease of use. Given its established commercial presence and expertise in infectious disease diagnostics, VivaChek is well-positioned to capitalize on global health initiatives and emerging disease threats. However, the company faces intense competition from larger players and regulatory hurdles in new markets. To sustain growth, it will likely need to expand its product pipeline, secure regulatory approvals in regions like Europe or the US, and forge partnerships with global health organizations. While financial details are undisclosed, the company's niche focus and operational history suggest a stable but moderate growth trajectory.

Upcoming Catalysts (preview)

• Q4 2026CE Mark approval for a new multiplex rapid test70% success
• TBDPartnership with WHO or UNITAID for HIV/syphilis self-tests50% success
• H1 2027Expansion into Southeast Asian or African markets via distributor agreement65% success